Australia's most trusted
source of pharma news
Posted 22 November 2021 AM
New York-based Kadmon Holding's Australian subsidiary, Kadmon Oceania, registered Rholistiq - its first-ever product on the ARTG last week - for patients with chronic graft-versus-host disease (GVHD).
The therapy, marketed in the US under brand name Rezurock, was snapped up by Sanofi last month when it acquired Kadmon in a deal worth US$1.9 billion.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.